Barrington lowered the firm’s price target on Paysign (PAYS) to $5 from $7 and keeps an Outperform rating on the shares following Q4 financial resu...
Source LinkTIPRANKS03-27
Barrington lowered the firm’s price target on Paysign (PAYS) to $5 from $7 and keeps an Outperform rating on the shares following Q4 financial resu...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
抱歉,当前请求异常(-1)
NYSE ORDER IMBALANCE 19986.0 SHARES ON BUY SIDE
Nyse Order Imbalance 95321.0 Shares on Sell Side
Nyse Order Imbalance 9259.0 Shares on Buy Side
FDA: Hikma Pharmaceuticals USA's Liraglutide 6 Mg/1 Ml Injections Available as of April 2 - Website
Usda Freezes Funds for Some Maine Educational Programs Over State's Refusal to Ban Transgender Women From Sports, Secretary Rollins Says
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial